Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes Fernandez-Rodriguez CM; Gutierrez ML; Lledo JL; Casas MLWorld J Gastroenterol 2011[Mar]; 17 (12): 1558-62Persistence of hepatitis B virus-DNA in the sera, peripheral blood mononuclear cells or in the liver of hepatitis B surface antigen (HBsAg)-negative patients with or without serological markers of previous exposure (antibodies to HBsAg and/or to HB-core antigen) defines the entity called occult hepatitis B infection (OBI). Co-infection with hepatitis B and hepatitis C viruses is frequent in highly endemic areas. While this co-infection increases the risk of liver disease progression, development of cirrhosis and hepatocellular carcinoma and also increases the rate of therapeutic failure to interferon-based treatments than either virus alone, a potentially negative effect of OBI on clinical outcomes and of therapeutic response to current antiviral regimes of patients with chronic hepatitis C remains inconclusive.|Antiviral Agents/therapeutic use[MESH]|Biomarkers/blood[MESH]|DNA, Viral/blood[MESH]|Disease Progression[MESH]|Hepacivirus/genetics/growth & development/immunology/*pathogenicity[MESH]|Hepatitis B Surface Antigens/blood[MESH]|Hepatitis B virus/genetics/growth & development/immunology/*pathogenicity[MESH]|Hepatitis B/diagnosis/*epidemiology/therapy/virology[MESH]|Hepatitis C Antibodies/blood[MESH]|Hepatitis C, Chronic/diagnosis/*epidemiology/therapy/virology[MESH]|Humans[MESH]|Liver/*virology[MESH]|Risk Factors[MESH]|Treatment Outcome[MESH]|Virus Activation[MESH]|Virus Replication[MESH] |
